Priya Singhal Biography and Net Worth

Insider of Biogen

Priya Singhal, M.D., M.P.H. is the Executive Vice President (E.V.P.) and Head of Development and interim Head of Research and Global Safety and Regulatory Sciences at Biogen. She also has oversight of Japan and China R&D. Dr. Singhal rejoined Biogen in 2020, having previously led Biogen’s Global Safety and Benefit Risk Management as the interim co-lead and Senior Vice President of Global Development. In her role as S.V.P. she managed the worldwide benefit-risk strategy for the portfolio as well as for the filings and approvals of six products. She joined Biogen in late 2012 as Vice President Clinical Trials and Benefit-Risk Management. Prior to her return to Biogen, Dr. Singhal served as Head of R&D and Manufacturing at Zafgen Inc., a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases. From 2008-2012 she was at Vertex Pharmaceuticals where she served as the Vice President, Medical Affairs and held roles of increasing seniority in Global Patient Safety. She began her drug-development career at Millennium Pharmaceuticals where she led benefit-risk for Velcade and two compounds in the development portfolio. Preceding her career in the Biotechnology Industry, Dr. Singhal completed her M.P.H. in International Health at Harvard School of Public Health and obtained her training in Internal Medicine in Mumbai, India.

What is Priya Singhal's net worth?: The estimated net worth of Priya Singhal is at least $1.02 million as of April 2nd, 2024. Dr. Singhal owns 4,886 shares of Biogen stock worth more than $1,020,685 as of April 27th. This net worth approximation does not reflect any other investments that Dr. Singhal may own. Learn More about Priya Singhal's net worth.
How do I contact Priya Singhal?: The corporate mailing address for Dr. Singhal and other Biogen executives is 225 BINNEY STREET, CAMBRIDGE MA, 02142. Biogen can also be reached via phone at (617) 679-2000 and via email at [email protected]. Learn More on Priya Singhal's contact information.
Has Priya Singhal been buying or selling shares of Biogen?: During the last quarter, Priya Singhal has sold $19,817.37 in shares of Biogen stock. Most recently, Priya Singhal sold 93 shares of the business's stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $213.09, for a transaction totalling $19,817.37. Following the completion of the sale, the insider now directly owns 4,886 shares of the company's stock, valued at $1,041,157.74. Learn More on Priya Singhal's trading history.
Who are Biogen's active insiders?: Biogen's insider roster includes Susan Alexander (EVP), Brian Posner (Director), Alfred Sandrock (insider), Priya Singhal (Insider), and Michel Vounatsos (CEO). Learn More on Biogen's active insiders.
Are insiders buying or selling shares of Biogen?: During the last twelve months, Biogen insiders bought shares 1 times. They purchased a total of 455 shares worth more than $101,255.70. During the last twelve months, insiders at the biotechnology company sold shares 8 times. They sold a total of 4,185 shares worth more than $1,172,646.90. The most recent insider tranaction occured on April, 2nd when insider Priya Singhal sold 93 shares worth more than $19,817.37. Insiders at Biogen own 0.6% of the company. Learn More about insider trades at Biogen.
Information on this page was last updated on 4/2/2024.

Priya Singhal Insider Trading History at Biogen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/2/2024	Sell	93	$213.09	$19,817.37	4,886
2/22/2024	Sell	262	$221.23	$57,962.26	4,886
2/16/2024	Sell	108	$221.49	$23,920.92	5,148
2/12/2024	Sell	419	$239.45	$100,329.55	4,516
12/11/2023	Sell	110	$248.00	$27,280.00	3,464
9/5/2023	Sell	431	$269.43	$116,124.33	3,354
7/3/2023	Sell	81	$282.87	$22,912.47	2,924
4/4/2023	Sell	91	$277.11	$25,217.01	2,843
3/28/2023	Sell	568	$270.06	$153,394.08	2,842

Priya Singhal Buying and Selling Activity at Biogen

Biogen Company Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $208.90

$199.10

$210.82

50 Day Range

MA: $212.55

$190.52

$230.07

2 Week Range

Now: $208.90

$189.44

$319.76

Volume

1,893,868 shs

Average Volume

1,185,437 shs

Market Capitalization

$30.42 billion

P/E Ratio

26.08

Dividend Yield

N/A

Beta

N/A

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>